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The Journal of Immunology
Activated Microglia Desialylate and Phagocytose Cells via
Neuraminidase, Galectin-3, and Mer Tyrosine Kinase
Koji Nomura, Anna Vilalta, David H. Allendorf, Tamara C. Hornik, and
Guy C. Brown
Activated microglia can phagocytose dying, stressed, or excess neurons and synapses via the phagocytic receptor Mer tyrosine
kinase (MerTK). Galectin-3 (Gal-3) can cross-link surface glycoproteins by binding galactose residues that are normally hidden
below terminal sialic acid residues. Gal-3 was recently reported to opsonize cells via activating MerTK. We found that LPS-
activated BV-2 microglia rapidly released Gal-3, which was blocked by calcineurin inhibitors. Gal-3 bound to MerTK on micro-
glia and to stressed PC12 (neuron-like) cells, and it increased microglial phagocytosis of PC12 cells or primary neurons, which was
blocked by inhibition of MerTK. LPS-activated microglia exhibited a sialidase activity that desialylated PC12 cells and could be
inhibited by Tamiflu, a neuraminidase (sialidase) inhibitor. Sialidase treatment of PC12 cells enabled Gal-3 to bind and opsonize
the live cells for phagocytosis by microglia. LPS-induced microglial phagocytosis of PC12 was prevented by small interfering RNA
knockdown of Gal-3 in microglia, lactose inhibition of Gal-3 binding, inhibition of neuraminidase with Tamiflu, or inhibition of
MerTK by UNC569. LPS-induced phagocytosis of primary neurons by primary microglia was also blocked by inhibition of
MerTK. We conclude that activated microglia release Gal-3 and a neuraminidase that desialylates microglial and PC12 surfaces,
enabling Gal-3 binding to PC12 cells and their phagocytosis via MerTK. Thus, Gal-3 acts as an opsonin of desialylated surfaces,
and inflammatory loss of neurons or synapses may potentially be blocked by inhibiting neuraminidases, Gal-3, or MerTK. The
Journal of Immunology, 2017, 198: 4792–4801.
P
hagocytosis is the cellular engulfment of large extracellular
particles, including other cells or parts of cells, such as
synapses. Cells are phagocytosed by competent phagocytes
(cells specialized in phagocytosis) if they possess “eat-me” signals
on their surface, lose “don’t-eat-me” signals, and/or bind opsonins
(1, 2). Opsonins are soluble proteins that, when bound to cells,
promote phagocytosis of those cells. Phagocytosis is greatly up-
regulated during inflammation, in part due to the release of op-
sonins (3). Phagocytes can phagocytose dead or dying cells, as
well as stressed, pathogenic, damaged, or excess cells, and ex-
cessive phagocytosis of otherwise viable cells may contribute to
pathology (2, 3). The code that determines whether a particular
cell (or cell part) is phagocytosed is still poorly understood but is
important in physiology and pathology.
Microglia are CNS-resident macrophages and are the main
phagocytes in the brain. In the absence of inflammation, “resting”
microglia phagocytose excess neurons and synapses and monitor
the brain for damage or pathogens (3, 4). When microglia detect
inflammatory stimuli they become “activated,” highly phagocytic,
and potentially neurotoxic, and they may contribute to ischemic,
traumatic, psychiatric, and neurodegenerative diseases (3, 5, 6).
Thus, it is important to understand what determines microglial
phagocytosis of neurons and neuronal parts.
Mer tyrosine kinase (MerTK) is a phagocytic receptor found on
myeloid lineage cells, including microglia (7). MerTK is upreg-
ulated on microglia in response to inflammation (8) and is re-
quired for phagocytosis of apoptotic cells (9), stressed neurons (8),
and synapses (10). MerTK can be activated by the opsonins growth
arrest–specific protein 6 or Protein S bound to phosphatidylserine
(7). More recently, galectin-3 (Gal-3) was identified as a MerTK
ligand and opsonin (11), but this interaction and what controls Gal-3
binding and opsonization of cells are poorly characterized.
Gal-3, also known as Mac-2 or LGALS3, is a protein expressed
in macrophages and microglia, and its expression is increased by
inflammatory activation (12–15). Gal-3 is found inside and outside
the cell, but the mechanism by which it is released is unclear (16).
Gal-3 has an N-terminal tail fused to a carbohydrate-recognition
domain (17), which preferentially binds to N-acetyl-lactosamine
(a disaccharide of galactose and N-acetyl-glucosamine) in glyco-
proteins or gangliosides (18).
The sugar chains of animal glycoproteins and glycolipids nor-
mally terminate in a sialic acid residue. Sialic acid is the generic
term for derivatives of the monosaccharide neuraminic acid, of
which the most common is N-acetylneuraminic acid. The terminal
sialic acid residue can be removed (a process known as desialy-
lation) by sialidases (also known as neuraminidases [Neus]) to
expose N-acetyl-lactosamine residues (i.e., the potential binding
site for Gal-3) (18). In mammals, there are four sialidases/Neus:
Neu1 is found predominantly in lysosomes but also on the cell
surface, Neu2 is found in the cytosol, Neu3 is found on the plasma
membrane, and Neu4 is found in lysosomes (19). Inflammatory
activation of macrophages causes translocation of Neu1 onto the
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cell surface, where it can desialylate glycoproteins and glycolipids
(20, 21). Neu1 is inhibited by Tamiflu, a drug developed to inhibit
viral Neus (20). It is not known whether Neu1 is expressed by, or
has any role in, microglia.
Apoptotic cells possess a sialidase activity that desialylates the
surface and promotes phagocytosis of the apoptotic cell (22).
Sialylation may inhibit phagocytosis of the cell by activating
Siglec receptors (receptors for sialic acid residues) on phagocytes
that inhibit phagocytosis by phagocytes. For example, desialyla-
tion of neurons promotes phagocytosis of neurons and neurites by
microglia, apparently by reduced activation of inhibitory Siglec-E
receptors (23), as well as by complement factors (24).
In this study, we investigated whether and how desialylation and
Gal-3 affect the phagocytosis of one cell by another, using BV-2
and PC12 cells as a model system relevant to microglial phago-
cytosis of neurons (25). As part of this investigation, we have
sought to determine whether inflammation causes desialylation
of microglia or neurons and, if so, which Neu is involved; whether
desialylation of neurons enables Gal-3 binding; whether Gal-3
binding promotes microglial phagocytosis of the neurons and,
if so, whether this is via binding MerTK; and whether blocking
Neu1, Gal-3, or MerTK prevents microglial phagocytosis of
neurons.
Materials and Methods
Materials
All chemicals and reagents were from Sigma-Aldrich (St. Louis, MO),
unless otherwise indicated. All cell culture and immunoblotting reagents
were from Invitrogen (Paisley, U.K.), unless otherwise indicated. Abs (with
dilutions for immunoblotting) were polyclonal anti–Galectin-3 (1:500;
Santa Cruz Biotechnology, Santa Cruz, CA), anti-MerTK (1:750; Fab-
Gennix, Frisco, TX), and anti–b-actin (Cell Signaling Technology, Dan-
vers, MA).
Cells and treatments
All experiments were performed in accordance with the U.K. Animals
(Scientific Procedures) Act (1986) and approved by the Cambridge Uni-
versity local ethical committee. The murine microglial cell line BV-2
(passage , 30) and the rat pheochromocytoma cell line PC12 were
maintained as described (26, 27). Where indicated, PC12 cells were dif-
ferentiated by 50 ng/ml 7S nerve growth factor. Primary mixed glial cul-
tures were prepared from cortex and neuronal–glial culture (85% neurons)
was prepared from cerebella of postnatal day-5–7 Wistar rats, as described
(28, 29). Dead neurons and neuronal debris were obtained by scraping cells
from live neuronal–glial culture (85% neurons) and then passing cells
through a 0.4 3 13-mm needle 10 times. The resulting dead neurons and
debris were stained with the succinimidyl ester form of TAMRA, and
30 mg (of protein) was added to microglia for 1 h.
BV-2 cells were stimulated with LPS from Salmonella enterica se-
rotype typhimurium (100 ng/ml), recombinant Gal-3 (rGal-3; 200 nM),
FIGURE 1. Gal-3 is secreted in response to LPS stimulation. BV-2 cells were exposed to vehicle or 100 ng/ml LPS for 1 or 4 h. (A) Representative Western
blot showing effect of LPS on Gal-3 expression and secretion. Gal-3 secretion was significantly induced by LPS in a time-dependent manner (1 h, p = 0.002 and 4
h, p, 0.001) (B), but total cellular Gal-3 was unchanged (Tukey post hoc test) (C). n = 3. Representative Western blot showing the effect of LPS and CsA (D) and
LPS and FK506 (F) on Gal-3 expression and secretion at 4 h (n = 3). (E and G) Quantification of three independent experiments from (D) and (F), respectively.
*p, 0.05, **p, 0.01, ***p, 0.001 versus 0 h, Tukey post hoc test. ###p, 0.01, LPS versus LPS + CsA, ##p, 0.01, LPS versus LPS + FK506, Tukey post hoc
test.
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and Neu from Vibrio cholera (0.1 U/ml) for 24 h, unless otherwise
indicated. For the Gal-3–binding assay, differentiated PC12 cells were
treated with staurosporine (500 nM) for 24 h. Where indicated, cells
were also treated with various inhibitors (UNC569 [500 nM], Milli-
pore, Billerica, MA; cyclosporin A [CsA; 100 ng/ml]; FK506 [1 mM],
Fujisawa Pharmaceutical, Osaka, Japan), Tamiflu (oseltamivir phos-
phate, 500 mM, unless otherwise indicated; LKT Laboratories, St.
Paul, MN), or Cli-095 (5 mM; InvivoGen) for 30 min prior to stimu-
lation. In all cases, inhibitors were used at concentrations predicted to
inhibit their target activity by ∼90%, without appreciable off-target
effects.
Phagocytosis and protein detection
Phagocytosis assays were performed as previously described (28–30).
Where indicated, 10,000 events were collected per well, and changes in
mean FL3 were analyzed using a flow cytometer (Accuri C6 flow
cytometer; BD). Western blot studies were performed using standard
procedures (31, 32), and membrane-bound secondary Abs were de-
tected using an Odyssey detection system (LI-COR, Lincoln, NE).
Where appropriate, culture media were concentrated to ∼40 times
using a 10-kDa cut-off filter (Millipore). MerTK–Gal-3 interaction was
assessed by coimmunoprecipitation using 250 mg of cellular protein
per sample immunoprecipitated by 2 mg of MerTK Ab and Pierce
Protein A/G Magnetic Beads (Thermo Scientific, Waltham, MA). Fur-
thermore, MerTK-immunoprecipitated beads were incubated with
200 nM TAMRA-stained rGal-3 at 37˚C for 2 h, and mean FL3 was
analyzed with an Accuri C6 flow cytometer. A Quantikine ELISA Kit
(R&D Systems, Minneapolis, MN) was used to measure TNF-a con-
centrations in the culture medium, according to the manufacturer’s in-
structions, and absorbance was measured using a FLUOstar OPTIMA
plate reader at 450 nm (specific wavelength) and 570 nm (nonspecific
wavelength).
Gal-3 release from cells was analyzed using Western blotting. After LPS
stimulation of BV-2 cells, serum-free culture medium was removed and
centrifuged at 1250 rpm at 4˚C for 5 min. Supernatant was then concen-
trated to ∼40 times using a 10-kDa cut-off filter. A constant amount of
concentrated supernatant and cell lysate was analyzed by Western blot.
Data were normalized to b-actin expression in cells (input).
RNA interference and Neu activity
RNA interference was performed by transfecting 10 nM Gal-3 small in-
terfering RNA (siRNA) or nontargeting control siRNA (Santa Cruz Bio-
technology) to BV-2 cells, using Lipofectamine 2000 (Invitrogen), for 24 h.
Cells were analyzed using a fluorescencemicroscope (DMI6000; Leica) or a
confocal microscope (IX81; Olympus). Neu activity was assessed using an
Amplex Red Neuraminidase Assay Kit (Life Technologies, Carlsbad, CA)
and by measuring FITC-conjugated peanut agglutinin (2 mg/ml) binding to
the cells.
Fluorescence polarization
Galectin-3 (Sigma-Aldrich) was labeled with Alexa Fluor 488 NHS Ester
(succinimidyl ester) in PBS at room temperature for 30 min, and free dye
was washed with desalting spin columns (Thermo Scientific). Labeling
was checked by MALDI mass spectrometry. Fluorescence anisotropy
measurements were recorded using a PHERAstar Plus multidetection
plate reader (BMG Labtech) equipped with a fluorescence polarization
optic module (lex = 485 nm, lem = 520 nm) at 25˚C. Each data point
is the mean of 200 flashes per well. The voltage gain was set by adjusting
the target mP values of labeled Gal-3 to that of fluorescein (35 mP).
Serial dilutions of MerTK (Sino Biological), modified citrus pectin
(ecoNugenics), and TREM2 ectodomain were made in PBS and added
together in a 1:1 ratio to a constant concentration of Gal-3 (35 nM; 44 mP).
Kd was estimated, assuming a 1:1 binding, using GraphPad Prism. Purified
TREM2 ectodomain was a kind gift from Roger Dodd and Peter St. George-
Hyslop (University of Cambridge).
Statistics
Experimental data are expressed as mean 6 SEM. Data were analyzed for
statistical significance using a general linear model ANOVA with Tukey
post hoc analysis using Minitab software. In all cases, statistical signi-
ficance was defined as p , 0.05.
FIGURE 2. Gal-3 binding to BV-2 and PC12 cells. (A) rGal-3 was labeled with TAMRA and added to a coculture of BV-2 and PC12 cells for 2 h. Gal-3
bound to many BV-2 cells (arrow a) but to only some PC12 cells associated with BV-2 cells (arrow b) and what appears to be phagocytosed cells within
microglia (arrows c and d). Binding was blocked by lactose (lower panels). Scale bar, 50 mm. PC12 cells (B) or BV-2 cells (C) were treated with vehicle,
Neu (0.1 U/ml), or Neu plus lactose (Lac; 50 mM) for 1 h, followed by 2 h with labeled rGal-3. Flow cytometry was used to quantify Gal-3 binding (n = 3).
(D) PC12 cells were treated with 100 or 500 nM of staurosporine (STS) or vehicle (Veh) for 24 h, TAMRA-labeled rGal-3 was applied to the cells for 2 h,
and binding was quantified by flow cytometry. Gal-3 bound more specifically to stressed (+100 nM STS) PC12 cells than to apoptotic PC12 cells (+500 nM
STS) (n = 3). **p , 0.01, ***p , 0.001 versus vehicle-treated control cells.
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Results
Gal-3
Gal-3 has been reported to mediate macrophage phagocytosis of
cells (11) and to be released by microglia (15), so we tested
whether Gal-3 mediated microglial phagocytosis. First, we in-
vestigated the time course of Gal-3 release from BV-2 microglia
in response to the TLR4 activator LPS. We found that LPS (100
ng/ml) induced a strong and rapid release of Gal-3 into the
culture media, such that its concentration increased from 100%
at the time of LPS addition to 382 6 41% after 1 h (p = 0.002,
Tukey post hoc test) and to 1116 6 41% after 4 h (p , 0.001,
Tukey post hoc test) (Fig. 1A, 1B). In contrast, LPS had no effect
on the protein expression of Gal-3 within microglia (Fig. 1C).
Thus, LPS caused Gal-3 release without changing expression
over this time course.
Serine phosphorylation of Gal-3 affects its cellular distribution
and activity (33), and LPS can activate the serine/threonine
phosphatase, calcineurin (34); therefore, we tested whether inhi-
bition of calcineurin would affect Gal-3 release. We found that
inhibition of calcineurin by CsA or FK506 significantly attenuated
Gal-3 secretion induced by LPS (CsA: p , 0.001, FK506: p =
0.022) without affecting Gal-3 expression in the cells (Fig. 1D–G).
To determine whether extracellular Gal-3 binds to cells, rGal-3
was fluorescently labeled and added to a coculture of BV-2 and
PC12 cells for 2 h. Fluorescence imaging and flow cytometry
indicated that Gal-3 bound to many microglia but only bound to
occasional PC12 cells, in particular those closely associated with
microglia (Fig. 2A, arrow a) and what appeared to be phagocy-
tosed cells within microglia (Fig. 2A, arrows b, c). Gal-3 binding
to PC12 cells and BV-2 cells was completely inhibited by 50 mM
lactose (Fig. 2A–C), indicating that Gal-3’s interaction with the
cells was entirely mediated by binding to sugar residues.
Whether Gal-3 bound to healthy, stressed, and/or dead cells was
tested with PC12 cells treated with the protein kinase inhibitor
staurosporine (500 nM). It induced significant cell death of PC12
cells over 24 h, whereas 100 nM staurosporine induced no sig-
nificant apoptosis or necrosis (Supplemental Fig. 1A). Staur-
osporine treatment substantially increased Gal-3 binding to PC12
cells, and binding was greater to the “stressed” cells (100 nM
staurosporine) than to the “apoptotic” cells (500 nM stauro-
sporine) (Fig. 2D). Thus, Gal-3 binds to stressed but viable cells,
as well as to dead cells.
We tested whether Gal-3 binding was regulated by sialylation of
the cell surface by adding isolated Neu (0.1 U/ml) to PC12 cells.
This resulted in desialylation of the cells, as indicated by the
binding of peanut agglutinin (Supplemental Fig. 1B), a lectin that
only binds desialylated cells (35). Neu-induced desialylation of
the cells also greatly enhanced Gal-3 binding to PC12 cells (Fig.
2B, Supplemental Fig. 2A) and colocalized with peanut agglutinin
FIGURE 3. Gal-3 mediates microglial phagocytosis of dead and live neurons. (A) BV-2 cells were treated or not with UNC569 (500 nM) and 200 nM
Gal-3 for 18 h, neuronal debris was added, and phagocytosis was quantified after 2 h. Absolute phagocytosis of the vehicle control cells: 2.47 6 0.42%
(n = 3). ***p , 0.001 versus vehicle control, Tukey post hoc test. ###p , 0.001 between indicated treatments. (B) Alternatively, live PC12 cells were
added for 4 h, and BV-2 phagocytosis of PC12 cells was quantified. Absolute phagocytosis of the vehicle control cells: 10.40 6 1.15% (n = 3). **p ,
0.01 versus vehicle control. ##p , 0.01 between indicated treatments. (C) LPS-induced phagoptosis of stressed but viable PC12 cells was significantly
attenuated by lactose but not sucrose. Absolute phagocytosis of the vehicle control cells: 9.45 6 1.57% (n = 3). **p , 0.01, ***p , 0.001 versus
vehicle control. ###p , 0.001 between the indicated treatments. (D) Representative Western blot showing the effect of Gal-3 knockdown. (E) LPS-
induced phagoptosis of stressed but viable PC12 cells was significantly attenuated by Gal-3 knockdown (p = 0.046). Absolute phagocytosis of the
vehicle control cells: 9.33 6 0.83% (n = 3). **p , 0.01 versus vehicle control. #p , 0.05 between indicated treatments. All p values were calculated
using the Tukey post hoc test. n.s., not significant.
The Journal of Immunology 4795
 by guest on D
ecem
ber 19, 2017
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
on the surface of target cells (Supplemental Fig. 2B), suggesting
that Gal-3 was binding to desialylated surfaces.
Gal-3 has been reported to opsonize cells for phagocytosis by
macrophages, but it is not known whether this is true for
microglial phagocytosis of live or dead neurons. We found that
addition of 200 nM rGal-3 substantially increased the phago-
cytosis of neuronal debris (sheared primary neurons, p , 0.001,
Tukey post hoc test) and live PC12 cells (p , 0.05, Tukey post
hoc test) (Fig. 3A, 3B).
Because LPS induced Gal-3 release (Fig. 1A, 1B), and addition
of Gal-3 induced microglial phagocytosis of PC12 cells (Fig. 3B),
we tested whether LPS induced microglial phagocytosis of PC12
cells and whether this was mediated by Gal-3. We found that LPS
did increase phagocytosis of live PC12 cells, and addition of
lactose (which blocked Gal-3 binding to PC12 cells, Fig. 2A)
inhibited this phagocytosis (p , 0.001, Tukey post hoc test)
(Fig. 3C). Note that neither LPS nor Gal-3 had any effect on the
viability of PC12 cells in the absence of microglia (Supplemental
Fig. 1C). Because calcineurin inhibitors decreased LPS-induced
Gal-3 release (Fig. 1D–G), we also tested whether they would
change LPS-induced phagocytosis of cells; we found that CsA and
FK506 inhibited phagocytosis of cells (Supplemental Fig. 3A,
3B). To directly test the role of Gal-3 in LPS-induced phagocy-
tosis, Gal-3 was knocked down by siRNA to 6.5 6 0.8% of its
control protein expression (Fig. 3D). Gal-3 knockdown signifi-
cantly inhibited LPS-induced phagocytosis of PC12 cells (p , 0.
05, Tukey post hoc test) (Fig. 3E). Thus, overall, the data indicate
that LPS causes microglia to release Gal-3, which binds to
stressed or dead neurons, opsonizing them for phagocytosis by
microglia.
MerTK
Gal-3 can opsonize cells for phagocytosis via the phagocytic re-
ceptor MerTK (11). To test whether the Gal-3–induced phagocytosis
of PC12 cells was mediated by MerTK, we added a MerTK-specific
inhibitor, UNC569 (500 nM) (36), and found that this completely
prevented the Gal-3–induced phagocytosis of neuronal debris
(p , 0.001) and live PC12 cells (p , 0.001, Tukey post hoc test)
(Fig. 3A, 3B). At this concentration, UNC569 had no effect on
microglial viability or proliferation (Supplemental Fig. 1D).
UNC569 also inhibited LPS-induced microglial phagocytosis
of live PC12 cells (p = 0.033, Tukey post hoc test) (Fig. 4B,
Supplemental Fig. 3C). LPS activation of the microglia increased
their phagocytosis of neuronal debris, and this increase was pre-
vented by blocking MerTK with UNC569 (p , 0.001) (Fig. 4A).
In primary cultures of rat cortical glia, microglial phagocytosis
of neuronal debris was significantly increased by LPS to 216.1 6
48.2% (p = 0.039, Tukey post hoc test), and this increase was
completely blocked by UNC569 (p = 0.028, Tukey post hoc test)
(Fig. 4C). In these same primary cultures, LPS greatly increased
TNF-a secretion (p , 0.001, Tukey post hoc test), but UNC569
did not inhibit this (p = 0.758, Tukey post hoc test) (Fig. 4D),
FIGURE 4. MerTK inhibitor UNC569 blocks LPS-induced phagocytosis. (A) BV-2 cells were treated or not with UNC569 (500 nM) for 30 min and then
were treated or not with 100 ng/ml LPS for 24 h. Neuronal debris was added for 2 h, and the amount of debris that was phagocytosed was quantified.
Absolute phagocytosis of the vehicle control cells: 6.57 6 2.47% (n = 3). (B) Alternatively, live PC12 cells were added for 4 h instead of debris, and the
amount of BV-2 phagocytosis of PC12 cells was quantified. Absolute phagocytosis of the vehicle control cells: 10.68 6 0.98% (n = 5). (C) Primary glial
cultures were treated or not with UNC569 (500 nM) for 30 min and then were treated or not with 100 ng/ml LPS for 24 h, neuronal debris was added for 2
h, and the amount of debris that was phagocytosed was quantified. Absolute phagocytosis of the vehicle control cells: 11.92 6 2.70% (n = 3). (D) TNF-a
levels in culture media were measured in the same experiment (mean 6 SEM; n = 4). *p , 0.05, ***p , 0.001 versus vehicle control in the absence of
LPS. #p , 0.05, ###p , 0.001 LPS versus LPS + UNC569. All p values were calculated using the Tukey post hoc test.
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indicating that UNC569 does not block LPS-induced phagocytosis
by inhibiting the inflammatory response.
To determine whether Gal-3 colocalizes with MerTK on
microglia, the binding of fluorescently labeled Gal-3 was compared
with the binding Abs to MerTK on control and LPS-activated
microglia. LPS increased Gal-3 binding and MerTK expression,
and Gal-3 bound predominantly to MerTK-expressing cells
(Fig. 5A). To test whether endogenous Gal-3 directly bound to
MerTK, MerTK was immunoprecipitated from control and LPS-
activated microglia, and the immunoprecipitate was subjected to
Western blot for MerTK and Gal-3. Endogenous Gal-3 was clearly
present in the MerTK immunoprecipitate but not that of a control
Ab, and LPS increased the amounts of MerTK and Gal-3 in the
immunoprecipitate (Fig. 5B, 5C). To test whether exogenous Gal-3
could bind to MerTK, MerTK was immunoprecipitated as before
from control and LPS-activated microglia using an anti-MerTK Ab
bound to beads, and the binding of fluorescent Gal-3 to these beads
was quantified by flow cytometry. Gal-3 bound to the MerTK im-
munoprecipitate but not to that of a control Ab, and the MerTK
binding was increased by LPS activation of the cells (p = 0.032
FIGURE 5. LPS upregulates MerTK expression and Gal-3 binding to BV-2 cells. (A) MerTK expression and Gal-3 binding were increased in response to
LPS stimulation. Note that Gal-3 can bind cells that express MerTK. Scale bar, 50 mm. (B) Representative coimmunoprecipitation. A total of 250 mg of
cellular lysates was immunoprecipitated with MerTK Ab or control IgG, and then Western blotted with MerTK and Gal-3 Abs. (C) Quantification of
coimmunoprecipitation. MerTK and Gal-3 physically interact, and this interaction was significantly increased by LPS stimulation. Black bars, vehicle
treatment; white bars, LPS treatment. *p , 0.05 versus vehicle (absence of LPS, immunoprecipitated with MerTK Ab). n = 3. (D) Gal-3 binding to
immunoprecipitated MerTK. Cellular lysates were immunoprecipitated with MerTK Ab (C terminus) or control IgG and then immunoprecipitated beads
were incubated with TAMRA-stained rGal-3 at 37˚C for 1 h. Mean FL3 of beads were measured. *p , 0.05 versus corresponding control IgG group. #p ,
0.05 versus vehicle (absence of LPS, immunoprecipitated with MerTK Ab). n = 3 independent experiments each.
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versus vehicle treatment with MerTK immunoprecipitated, Tukey
post hoc test) (Fig. 5D).
To test whether Gal-3 bound directly to MerTK, rather than
through some intermediate, we assayed whether purified Gal-3
bound to purified MerTK extracellular domain by fluorescence
polarization. The fluorescence polarization of fluorescently labeled
Gal-3 was substantially enhanced by the addition of increasing
concentrations of MerTK ectodomain, indicating direct binding
(Supplemental Fig. 4). This fluorescence enhancement was half
saturated at 155 nM MerTK, indicating a Kd = 155 nM, assuming
a 1:1 binding. As positive control, we used modified citrus pectin,
which is known to bind Gal-3 with high affinity; we found that this
enhanced the fluorescence polarization of Gal-3 to a similar extent
as MerTK ectodomain. As negative control, we used the purified
ectodomain of the microglial receptor TREM2 and found that this
had no significant binding to Gal-3 (Supplemental Fig. 4).
Taken together, these findings suggest that Gal-3 binds toMerTK
on microglia and can opsonize cells for microglial phagocytosis
via MerTK.
Neuraminidase
LPS has been found to upregulate Neu1 on the surface of mac-
rophages, and the activity of this Neu has been found to be inhibited
by Tamiflu (20). We found that LPS activation of microglia sig-
nificantly increased Neu activity on the cellular surface (158 6
11%) and in culture medium (171 6 17%) (p , 0.001, p = 0.037,
respectively, Tukey post hoc test) (Fig. 6), and the LPS-induced
Neu activity on the cells and in the medium was completely
inhibited by 500 mM Tamiflu (Fig. 6).
We tested whether the sialidase activity exhibited by activated
microglia was sufficient to desialylate PC12 cells. Peanut agglu-
tinin binding to PC12 cells was unaffected by incubation with
medium from nonactivated microglia, but it was increased 3-fold
by incubation with medium from LPS-activated microglia; for
comparison, it was increased 6-fold by incubation with 0.1 U/ml
Neu (Fig. 7A). This indicates that the Neu activity secreted by
activated microglia was sufficient to desialylate PC12 cells and
that the level of desialylation is comparable to that induced by
added Neu.
Because activation of microglia with LPS caused a Neu activity
that desialylated PC12 cells, we tested whether Neu alone was
sufficient to induce microglial phagocytosis of PC12 cells. Addi-
tion of extracellular Neu increased microglial phagocytosis of live
PC12 cells to 316 6 18% (p , 0.001, Tukey post hoc test)
(Fig. 7B). Note that addition of Neu to PC12 cells alone had ab-
solutely no effect on their viability (Supplemental Fig. 3C). Ad-
dition of Gal-3 together with Neu increased microglial
phagocytosis of the PC12 cells to 449 6 24% (p , 0.001 versus
Neu alone, Tukey post hoc test) (Fig. 7B). Furthermore, LPS-
induced phagocytosis of live PC12 cells was inhibited by the
Neu inhibitor Tamiflu (p = 0.001 at 100 mM, p , 0.001 at 500
mM, Tukey post hoc test) (Fig. 7C). Thus, activated microglia
exhibit Neu activity, inhibition of this Neu activity prevents
phagocytosis of live PC12 cells by activated microglia, and Neu
alone is sufficient to induce phagocytosis, which is enhanced by
added Gal-3.
Discussion
Gal-3 has been described as a ligand for MerTK on macrophages
(11). Consistent with this, we found that MerTK and Gal-3
colocalized, Gal-3 induced microglial engulfment of cells, and
this engulfment was blocked by the MerTK inhibitor UNC569.
Gal-3 was rapidly released from LPS-activated microglia and
bound to microglial cells and PC12 cells (especially to stressed or
dying PC12 cells), as well as to MerTK from microglia. These and
previous findings (11) suggest that Gal-3 can opsonize cells for
phagocytosis by binding MerTK on phagocytes and some factors
on target cells. Gal-3 binding to cells was blocked by lactose, as
was LPS-induced phagocytosis of PC12 cells. Thus, Gal-3 appears
to bind phagocyte and target cells via binding sugars, and this
binding appears to be required for phagocytosis. Gal-3 knockdown
prevented LPS-induced microglial engulfment of live PC12 cells.
Thus, Gal-3 appears to act as an opsonin mediating the phago-
cytosis of cells by activated microglia.
What does Gal-3 bind to on target cells? Our results indicate
that Gal-3 binds to desialylated sugar chains, as indicated by
inhibition of cellular binding by lactose, which greatly increased
binding after desialylation of the cells, and colocalization of
FIGURE 6. Neu in microglia. (A and B) BV-2 cells were exposed to vehicle or 100 ng/ml LPS for 24 h, following pretreatment with different con-
centrations of Tamiflu or vehicle. Neu activity was increased by LPS on the cellular surface (A) and in medium (B). n = 3 independent experiments for each;
measurements were made in triplicate for each experiment. *p , 0.05, ***p , 0.001 versus untreated control. #p , 0.05, ##p , 0.01, ###p , 0.001 versus
LPS-treated control.
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binding with peanut agglutinin. We cannot be sure that Gal-3 did
not enter the cells over the time course of the binding experi-
ments; however, this seems unlikely because lactose completely
prevented association with the cells. Thus, Gal-3 may act as an
opsonin for desialylated cells or parts of cells that are desialy-
lated.
LPS-activated microglia released a Neu activity into the
medium, and this Neu activity was sufficient to desialylate PC12
cells. Neu1 may be responsible for this Neu activity, because it
was inhibited by Tamiflu. This is consistent with reports that LPS
and other inflammatory stimuli cause translocation of Neu1 to the
cell surface of macrophages and other leukocytes, where it can
desialylate cell surface glycoproteins (20, 21, 37). Added Neu
and Gal-3 greatly increased microglial phagocytosis of PC12
cells. LPS-induced phagocytosis of PC12 cells was prevented by
Tamiflu, lactose, knockdown of Gal-3, or inhibition of MerTK.
This is consistent with LPS inducing microglial release of
Neu that desialylates PC12 cells, allowing Gal-3 to bind and
FIGURE 7. Activated microglia exhibit a Tamiflu-inhib-
itable Neu activity that enhances phagocytosis of PC12
cells. (A) Fresh culture medium (Veh) or culture medium
incubated with BV-2 with or without LPS for 24 h was
incubated with PC12 cells for 2 h (or alternatively, 0.1 U/ml
Neu was added), and binding of peanut agglutinin was
measured by flow cytometry. (B) Neu enhances microglial
phagocytosis of live PC12 cells. BV-2 cells were exposed to
vehicle or 0.1 U/ml Neu, with or without 200 nM Gal-3, for
1 h. Absolute phagocytosis of the vehicle control cells:
12.50 6 1.19%. (C) LPS-induced microglial phagocytosis
of live PC12 cells is inhibited by Tamiflu. Absolute
phagocytosis of the vehicle control cells: 11.61 6 1.07%.
n = 3 for phagocytosis assay, and n = 4 for Neu activity
assay. *p , 0.05 versus untreated PC12 cells, ***p , 0.001
versus untreated control. ##p , 0.01, ###p , 0.001 between
the indicated treatments. All p values were calculated using
the Tukey post hoc test. n.s., not significant.
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opsonize PC12 cells also via binding and activating MerTK on the
microglia.
Gal-3 is certainly not the only opsonin, and MerTK is not the
only receptor, that mediates microglial phagocytosis of neurons.
Our findings that lactose inhibition of Gal-3 binding, Gal-3
knockdown, and UNC569 inhibition of MerTK do not fully in-
hibit LPS-induced phagocytosis of cells (Figs. 3C, 3E, 4B) are
consistent with other opsonins and receptors being involved. Other
opsonins that are known to mediate phagocytosis via MerTK are
growth arrest–specific protein 6 and Protein S, which bind to
exposed phosphatidylserine, whereas vitronectin receptors bind to
exposed phosphatidylserine via the opsonin MFG-E8, the LRP1
receptor binds to calreticulin exposed on cells, and the CR3 re-
ceptor binds to iC3b-opsonized and, possibly, C1q-opsonized
cells (2). The point is not that Gal-3 is the only opsonin but rather
that it is a novel opsonin that binds a novel eat-me signal (i.e.,
desialylated cells). It is possible that Gal-3 and MerTK are both
required for phagocytosis but do not directly interact to mediate
phagocytosis. However, the finding in this study that they directly
interact suggests that their coinvolvement is due to their direct
interaction as opsonin and receptor.
In principle, Gal-3 could mediate phagocytosis by binding other
phagocytic receptors, as well as MerTK. Because the binding of
Gal-3 to microglia was prevented by lactose, it is possible that the
binding of Gal-3 to MerTK (and potentially other receptors) was
mediated by the carbohydrate recognition domain of Gal-3 binding
to desialylated MerTK (and potentially other receptors). However,
MerTK appears to be the main receptor by which Gal-3 increases
phagocytosis, because a MerTK inhibitor prevented Gal-3–induced
phagocytosis (Fig. 3A, 3B). We did not test directly whether
MerTK mediated the phagocytosis of desialylated cells, but this
seems likely given that MerTK mediated Gal-3–induced phago-
cytosis, and Gal-3 bound to desialylated cells.
Gal-3 increases after neonatal brain ischemia, and Gal-3–
knockout mice are protected from the subsequent neuronal loss
(38). We found that MerTK mutant rats were protected from
transient ischemia–induced delayed neuronal loss mediated by
microglial phagocytosis (8). This may be consistent with delayed
neuronal loss after brain ischemia being due to Gal-3–, Neu1-, and
MerTK-mediated microglial phagocytosis. Brain ischemia up-
regulates the microglial expression of MerTK (8) and Gal-3 (39),
and this 7may be mediated, in part, by TLR4, because TLR4 is
highly expressed in microglia during ischemia (e.g., 40) and has
multiple potential ligands, including HMGB1, that are upregulated
by ischemia (41).
Gal-3 appears to mediate microglial phagocytosis of myelin,
which may contribute to demyelination or myelin debris clearance
(42, 43), and the results from this study suggest that this might be
a result of the desialylation of the myelin. Activated microglia can
phagocytose live glioma cells (44), and the mechanisms described
in this article might contribute to protection against brain cancers.
Microglia phagocytose activated neutrophils to protect the brain
from excessive inflammation (45), and activated neutrophils are
known to desialylate via Neu1 translocation (37), which might
contribute to their removal via the mechanisms described in this
article. We recently found that Gal-3 is upregulated in a mouse
model of brain trauma and that Gal-3–knockout mice have less
neuronal loss posttrauma, consistent with Gal-3 mediating this
neuronal loss (46).
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